Nigrosome-1 imaging and neuromelanin contrast have been identified as good radiological biomarkers of dopaminergic nigral degeneration in Parkinson's disease (PD) pathology. We evaluated the sensitivity of quantitative Susceptibility-Mapping Weighted Imaging (SMWI) derived from Quantitative Susceptibility Mapping (QSM) and neuromelanin sensitive (NMS) imaging in differentiating a case control cohort of PD patients. Region-of-interest analysis of the substantia nigra on both QSM/SMWI and NMS offered excellent differentiation of PD and healthy controls. However, QSM/SMWI offered more robust disease classification compared to NMS and might be preferred for use in the clinical setting.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords